Product Code: ETC13129893 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Non-alcoholic Steatohepatitis Market was valued at USD 3.5 Billion in 2024 and is expected to reach USD 7.8 Billion by 2031, growing at a compound annual growth rate of 12.20% during the forecast period (2025-2031).
The global non-alcoholic steatohepatitis (NASH) market is experiencing significant growth driven by the increasing prevalence of obesity and related metabolic disorders worldwide. NASH is a progressive liver disease characterized by fat accumulation in the liver, inflammation, and ultimately, liver damage. The market is witnessing a surge in research and development activities focused on developing novel therapeutic interventions to address this unmet medical need. Key market players are investing in clinical trials to bring effective treatments to market, including pharmaceuticals targeting inflammation, fibrosis, and metabolic pathways. Additionally, the market is benefiting from collaborations between pharmaceutical companies and academic institutions to enhance understanding of NASH pathogenesis and improve patient outcomes. Overall, the global NASH market is poised for substantial expansion in the coming years as awareness and diagnosis rates continue to rise.
The Global Non-alcoholic Steatohepatitis (NASH) market is experiencing significant growth due to the rising prevalence of obesity and metabolic disorders worldwide. Key trends in the market include increasing research and development activities focused on developing novel therapies for NASH, growing awareness among healthcare professionals and patients, and advancements in diagnostic technologies for early detection. Opportunities in the market lie in the potential for collaborations between pharmaceutical companies and research institutions to accelerate drug development, the expanding pipeline of NASH treatment candidates, and the untapped market potential in emerging economies. With the increasing burden of NASH on healthcare systems globally, there is a growing need for effective treatments, making the market ripe for innovation and investment.
The Global Non-alcoholic Steatohepatitis (NASH) market faces several challenges, including the lack of standardized diagnostic tools and treatment options, as well as the complexity of the disease itself. NASH is a progressive liver disease with no approved pharmacological therapies, making it difficult for healthcare providers to effectively manage and treat patients. Additionally, the high prevalence of risk factors such as obesity and diabetes further complicates the landscape of NASH treatment. Moreover, the regulatory pathways for drug approval in this therapeutic area are still evolving, leading to uncertainties for pharmaceutical companies investing in NASH research and development. Overall, the complexities surrounding diagnosis, treatment, and regulatory pathways present significant challenges for stakeholders in the Global NASH market.
The Global Non-alcoholic Steatohepatitis (NASH) Market is primarily driven by the rising prevalence of obesity and metabolic disorders, which are key risk factors for NASH development. Additionally, the increasing awareness about the potential complications of untreated NASH, such as liver cirrhosis and hepatocellular carcinoma, is driving the demand for diagnostic and treatment options. The high unmet medical need in the NASH market has spurred research and development activities focused on novel therapeutics and diagnostics, further propelling market growth. Moreover, the growing emphasis on early diagnosis and intervention to prevent disease progression is boosting the adoption of NASH management strategies. Overall, factors such as lifestyle changes, unhealthy dietary habits, and sedentary lifestyles are contributing to the increasing incidence of NASH, thereby fueling market expansion.
Government policies related to the Global Non-alcoholic Steatohepatitis (NASH) Market primarily focus on promoting public health initiatives to address the rising prevalence of NASH. Many governments have implemented regulations to encourage healthier eating habits, increase physical activity levels, and reduce obesity rates, all of which are key risk factors for NASH. Additionally, some countries have allocated funding for research and development in the field of NASH treatment and prevention, aiming to improve healthcare outcomes and reduce the economic burden associated with NASH-related healthcare costs. Governments also collaborate with healthcare organizations and pharmaceutical companies to streamline drug approval processes and ensure timely access to innovative treatments for NASH patients. Overall, government policies aim to create a supportive environment for the development of effective strategies to combat NASH and improve public health outcomes on a global scale.
The Global Non-alcoholic Steatohepatitis (NASH) market is poised for significant growth in the coming years due to the increasing prevalence of obesity and metabolic disorders worldwide. The market is expected to be driven by the development of novel treatment options, including emerging therapies targeting specific pathways involved in NASH pathogenesis. Additionally, the rising awareness about the disease among healthcare providers and patients, coupled with the growing demand for effective therapeutic interventions, will further propel market expansion. However, challenges such as high development costs, stringent regulatory requirements, and the lack of specific diagnostic tools may hinder market growth to some extent. Overall, the Global NASH market presents lucrative opportunities for pharmaceutical companies and healthcare stakeholders to address the unmet medical needs in this field and improve patient outcomes.
The global non-alcoholic steatohepatitis (NASH) market shows regional variations in terms of market dynamics and treatment approaches. In Asia, the NASH market is poised for significant growth due to the increasing prevalence of obesity and metabolic disorders. North America leads the market with a well-established healthcare infrastructure and high awareness about NASH. In Europe, government initiatives promoting early diagnosis and treatment are driving market growth. The Middle East and Africa region is witnessing a rise in NASH cases due to changing lifestyles and dietary habits. Latin America is also experiencing a growth in the NASH market, with increased investment in healthcare infrastructure and rising awareness about liver diseases. Overall, these regional insights highlight the diverse opportunities and challenges present in the global NASH market.
Global Non-alcoholic Steatohepatitis Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Non-alcoholic Steatohepatitis Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Non-alcoholic Steatohepatitis Market Revenues & Volume, 2021 & 2031F |
3.3 Global Non-alcoholic Steatohepatitis Market - Industry Life Cycle |
3.4 Global Non-alcoholic Steatohepatitis Market - Porter's Five Forces |
3.5 Global Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.7 Global Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Sales Channel, 2021 & 2031F |
3.8 Global Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Disease Cause, 2021 & 2031F |
3.9 Global Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Global Non-alcoholic Steatohepatitis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Non-alcoholic Steatohepatitis Market Trends |
6 Global Non-alcoholic Steatohepatitis Market, 2021 - 2031 |
6.1 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Vitamin E and Pioglitazone, 2021 - 2031 |
6.1.3 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Ocaliva, 2021 - 2031 |
6.1.4 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Elafibranor, 2021 - 2031 |
6.1.5 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Selonsertib and Cenicriviroc, 2021 - 2031 |
6.1.6 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Obeticholic Acid, 2021 - 2031 |
6.1.7 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Others, 2021 - 2031 |
6.2 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Sales Channel, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Hospital Pharmacy, 2021 - 2031 |
6.2.3 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Online Providers, 2021 - 2031 |
6.2.4 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Retail Pharmacy, 2021 - 2031 |
6.3 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Disease Cause, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Hypertension, 2021 - 2031 |
6.3.3 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Heart Disease, 2021 - 2031 |
6.3.4 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By High Blood Lipid, 2021 - 2031 |
6.3.5 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Type 2 Diabetes, 2021 - 2031 |
6.3.6 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Obesity, 2021 - 2031 |
6.4 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By End User, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Hospitals, 2021 - 2031 |
6.4.3 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Clinics, 2021 - 2031 |
6.4.4 Global Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Homecare settings, 2021 - 2031 |
7 North America Non-alcoholic Steatohepatitis Market, Overview & Analysis |
7.1 North America Non-alcoholic Steatohepatitis Market Revenues & Volume, 2021 - 2031 |
7.2 North America Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
7.4 North America Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Sales Channel, 2021 - 2031 |
7.5 North America Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Disease Cause, 2021 - 2031 |
7.6 North America Non-alcoholic Steatohepatitis Market, Revenues & Volume, By End User, 2021 - 2031 |
8 Latin America (LATAM) Non-alcoholic Steatohepatitis Market, Overview & Analysis |
8.1 Latin America (LATAM) Non-alcoholic Steatohepatitis Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
8.4 Latin America (LATAM) Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Sales Channel, 2021 - 2031 |
8.5 Latin America (LATAM) Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Disease Cause, 2021 - 2031 |
8.6 Latin America (LATAM) Non-alcoholic Steatohepatitis Market, Revenues & Volume, By End User, 2021 - 2031 |
9 Asia Non-alcoholic Steatohepatitis Market, Overview & Analysis |
9.1 Asia Non-alcoholic Steatohepatitis Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
9.4 Asia Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Sales Channel, 2021 - 2031 |
9.5 Asia Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Disease Cause, 2021 - 2031 |
9.6 Asia Non-alcoholic Steatohepatitis Market, Revenues & Volume, By End User, 2021 - 2031 |
10 Africa Non-alcoholic Steatohepatitis Market, Overview & Analysis |
10.1 Africa Non-alcoholic Steatohepatitis Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
10.4 Africa Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Sales Channel, 2021 - 2031 |
10.5 Africa Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Disease Cause, 2021 - 2031 |
10.6 Africa Non-alcoholic Steatohepatitis Market, Revenues & Volume, By End User, 2021 - 2031 |
11 Europe Non-alcoholic Steatohepatitis Market, Overview & Analysis |
11.1 Europe Non-alcoholic Steatohepatitis Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
11.4 Europe Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Sales Channel, 2021 - 2031 |
11.5 Europe Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Disease Cause, 2021 - 2031 |
11.6 Europe Non-alcoholic Steatohepatitis Market, Revenues & Volume, By End User, 2021 - 2031 |
12 Middle East Non-alcoholic Steatohepatitis Market, Overview & Analysis |
12.1 Middle East Non-alcoholic Steatohepatitis Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Non-alcoholic Steatohepatitis Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
12.4 Middle East Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Sales Channel, 2021 - 2031 |
12.5 Middle East Non-alcoholic Steatohepatitis Market, Revenues & Volume, By Disease Cause, 2021 - 2031 |
12.6 Middle East Non-alcoholic Steatohepatitis Market, Revenues & Volume, By End User, 2021 - 2031 |
13 Global Non-alcoholic Steatohepatitis Market Key Performance Indicators |
14 Global Non-alcoholic Steatohepatitis Market - Export/Import By Countries Assessment |
15 Global Non-alcoholic Steatohepatitis Market - Opportunity Assessment |
15.1 Global Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
15.3 Global Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Sales Channel, 2021 & 2031F |
15.4 Global Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Disease Cause, 2021 & 2031F |
15.5 Global Non-alcoholic Steatohepatitis Market Opportunity Assessment, By End User, 2021 & 2031F |
16 Global Non-alcoholic Steatohepatitis Market - Competitive Landscape |
16.1 Global Non-alcoholic Steatohepatitis Market Revenue Share, By Companies, 2024 |
16.2 Global Non-alcoholic Steatohepatitis Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |